We are looking for partnering opportunities on new assets (small molecules, biologics or advanced therapies) in research or preclinical development stages that could be useful for the treatment of dermatological diseases.
Preferably, the assets should target immuno-inflammatory pathways or be suitable for dermato-oncological or rare skin indications, and demonstrate strong scientific rationale, including in vitro and in vivo evidences of efficacy, if available.
Our interest
New assets in advanced research or preclinical development stages
